GBT Global Blood Therapeutics Inc

Global Blood Therapeutics Inc is a clinical-stage biopharmaceutical company in the United States. Its major focus lies on developing therapeutics for the treatment of blood-based disorders such as red blood cell sickling.

$26.17  +0.71 (2.79%)
As of 05/27/2022 15:59:56 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  08/12/2015
Outstanding shares:  65,098,164
Average volume:  1,582,899
Market cap:   $1,642,426,678
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BZ05388
Valuation   (See tab for details)
PE ratio:   -5.35
PB ratio:   12.36
PS ratio:   7.79
Return on equity:   -231.03%
Net income %:   -146.82%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy